The Hematology and Eye Disease

  • Liqiang Wei
  • Jingwen Wang
  • Weihong Yu
Part of the Advances in Visual Science and Eye Diseases book series (AVSED, volume 3)


Blood diseases are diseases that arise spontaneously in the hematopoietic system or affect the hematopoietic system and are accompanied by abnormal blood changes. They include erythrocyte diseases, granulocyte diseases, lymphatic diseases, plasma cell diseases, myeloproliferative diseases, bleeding, thrombotic diseases, etc. Blood diseases can involve various systems and organs of the body. Their early manifestations are often not typical. Most patients with hematological disease first visit in other departments, which leads to misdiagnosis and missed diagnosis. It is reported that about 90% of blood diseases will involve the eyes, but in clinical practice ophthalmologists pay little attention to ischemic eye diseases caused by vascular diseases. If we re-examine the relationship between blood diseases and eye diseases from the perspective of integrated medicine, we can find that eye diseases have the characteristics reflecting the abnormal changes of the blood components: (1) changes in blood components can cause changes in the tone of blood vessels, and thus may cause tissue color or tone abnormalities, such as pale conjunctiva caused by anemia, yellow scleral caused by hemolytic jaundice, and cobalt blue sclera caused by iron-deficiency anemia; (2) ischemia is often accompanied by changes in bleeding, which is mainly due to the destruction of coagulation balance. The pathologic essence of tumor determines that it has the following characteristics: (a) atypical; (b) able to growth; (c) able to diffuse; and (d) able to infiltrate and metastasize (as with malignant tumor). The latter three represent the main causes of tumor damage to tissues and organs. Therefore, eye tumors that have their origins in the hematopoietic system usually have the features of the two. Following the concept of integrated medicine, we should, in clinical practice, have the holistic treatment concept of “holistic analysis and systemic balance” and work with blood department in close cooperation in diagnosis and treatment. We should be concerned about not only the visual impairment caused by blood disease itself, but also the side effects of treatment.


  1. 1.
    Lang GE, Lang SJ. Ocular findings in hematological disease. Ophthalmology. 2011;108(10):981–93.CrossRefGoogle Scholar
  2. 2.
    Gan NY, King LL, Teoh SC. Ocular masquerade syndrome as a herald of progression of acute myelogenous leukemia. Ann Hematol. 2011;90(3):361–2.CrossRefPubMedGoogle Scholar
  3. 3.
    Schachat AP, Markowitz JA, Guyer DR, et al. Ophthalmic manifestations of leukemia. Arch Ophthalmol. 1989;107:697–700.CrossRefPubMedGoogle Scholar
  4. 4.
    Wang GH. Ocular signs of acute leukemia. J Ophthalmol Combining Chin Tradit Med West Med. 1998;16(3):177–8.Google Scholar
  5. 5.
    Li XH, Zhang AC, Zhang Y, et al. Ocular manifestations of pediatric acute leukemia. J Appl Clin Pediat. 2001;16(2):122–3.Google Scholar
  6. 6.
    Russo V, Scott IU, Querques G, et al. Orbital and ocular manifestations of acute childhood leukemia: clinical and statistical analysis of 180 patients. Eur J Ophthalmol. 2008;18:619–23.CrossRefPubMedGoogle Scholar
  7. 7.
    Wei LQ, Wang JW, Feng N, et al. MRI and PET/CT manifestations and clinical analysis of mucosa-associated lymphoid tissue lymphoma of eye adnexa. J Clin Hematol. 2012;25(7):437–9.Google Scholar
  8. 8.
    Ferry JA, Fung CY, Zukerbery L, et al. Lymphoma of the ocular adnexa: a study of 353 cases. Am J Surg Pathol. 2007;31:170–84.CrossRefPubMedGoogle Scholar
  9. 9.
    Paik J-S, Cho W-K, Lee S-E, et al. Ophthalmologic outcomes after chemotherapy and/or radiotherapy in non-conjunctival ocular adnexal MALT lymphoma. Ann Hematol. 2012;91:1393–401.CrossRefPubMedGoogle Scholar
  10. 10.
    Davis JL. Intraocular lymphoma: a clinical perspective. Eye. 2013;27:153–62.CrossRefPubMedGoogle Scholar
  11. 11.
    Raparia K, (Jeff) Chang C-C, Chevez-Barrios P. Intraocular lymphoma. Arch Pathol Lab Med. 2009;133:1233–7.PubMedGoogle Scholar
  12. 12.
    Chin KJ, Kempin S, Milman T, et al. Ocular manifestations of multiple myeloma: three cases and a review of the literature. Optometry. 2011;82:224–30.CrossRefPubMedGoogle Scholar
  13. 13.
    Dou XY, Du X, Sima J, et al. Analysis of the clinical ocular features of true polycythemia with ocular symptoms as the initial manifestations. Chin J Pract Ophthalmol. 2006;24(6):631–3.Google Scholar
  14. 14.
    Kezuka T, Usui N, Suzuki E, et al. Ocular complications in myelodysplastic syndromes as preleukemic disorders. Jpn J Ophthalmol. 2005;49(5):377–83.CrossRefPubMedGoogle Scholar
  15. 15.
    Wei LQ, Wang JW, Feng N, et al. Treatment of concomitant multiple myeloma and reversible posterior leukoencephalopathy syndrome with bortezomib plus dexamethasone: a case study and literature review. J Clin Hematol. 2012;25(5):597–600.Google Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. and People's Medical Publishing House, PR of China 2020

Authors and Affiliations

  • Liqiang Wei
    • 1
  • Jingwen Wang
    • 1
  • Weihong Yu
    • 2
  1. 1.Department of HematologyBeijing Tongren Hospital, Capital Medical UniversityBeijingChina
  2. 2.Department of OphthalmologyPeking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina

Personalised recommendations